A novel system for evaluation of drug mixtures for potential efficacy in treating multidrug resistant cancers
The DOI matches its Crossref record.
Abstract
Multidrug resistant (MDR) cancer is difficult to treat. Chemicals that are effective MDR modulators have never exited clinical trials as FDA approved products due to side effects. It has been hypothesized that using a combination of chemotherapeutics with a mixture of MDR modulators (each with different side effects) may lead to useful treatment strategies. Because the experimental space for combination treatments can be large, this space may be impracticable to explore using animal studies. Here we describe an in vitro system based on microfabrication and cell culture that can potentially be used to explore large experimental spaces efficiently. The Microscale Cell Culture Analog (µCCA) concept mimics the body's response using interconnected compartments that represent various tissues or organs. A µCCA is based on the structure of an appropriate physiologically based pharmacokinetic (PBPK) model and emulates the body's dynamic response to exposure to various drugs and chemicals. For this problem we have chosen a µCCA with living cells representing the liver (HepG2/C3A), bone marrow (MEG‐01), uterine cancer (MES‐SA), and a MDR variant of uterine cancer (MES‐SA/DX‐5). In proof of concept experiments we found in 24 h “acute” exposures and 72 h treatments that the µCCA system predicts combining the chemotherapeutic, doxorubicin, with cyclosporine and nicardipine, as MDR modulators will have greater efficacy than using doxorubicin by itself or with either modulator alone. This combined strategy is selective in inhibiting MES‐SA/DX‐5 cell proliferation and may prove to be advantageous in vivo by specifically targeting MDR cancer with acceptable side‐effects. This cell specific synergy was not observed in traditional 96‐well plate assays. By combining the µCCA with a PBPK model, appropriate drug doses and area under the curve exposure for in vivo trials can be extrapolated directly from the results obtained with this device. This device and approach should be useful in screening potential drug/modulator combinations to determine candidate treatments for MDR cancer. Indeed this approach may be useful for in vitro evaluation of human response to a wide range of exposures to mixtures of chemicals or drugs. Biotechnol. Bioeng. 2009;103: 187–198. © 2008 Wiley Periodicals, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Bhatia, S. N., & Ingber, D. E. (2014) · Nature Biotechnology · doi:10.1038/nbt.2989 · Cited by 3,305
Organs-on-chips at the frontiers of drug discovery
Esch, E. W., Bahinski, A., & Huh, D. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4539 · Cited by 1,185
A guide to the organ-on-a-chip
Leung, C. M., de Haan, P., Ronaldson-Bouchard, K., Kim, G.-A., Ko, J., Rho, H. S., Chen, Z., Habibovic, P., Jeon, N. L., Takayama, S., et al. (2022) · Nature Reviews Methods Primers · doi:10.1038/s43586-022-00118-6 · Cited by 1,116
Self-citationAdvances in organ-on-a-chip engineering
Zhang, B., Korolj, A., Lai, B. F. L., & Radisic, M. (2018) · Nature Reviews Materials · doi:10.1038/s41578-018-0034-7 · Cited by 1,017
Alternative (non-animal) methods for cosmetics testing: current status and future prospects—2010
Adler, S., Basketter, D., Creton, S., Pelkonen, O., van Benthem, J., Zuang, V., Andersen, K. E., Angers-Loustau, A., Aptula, A., Bal-Price, A., et al. (2011) · Archives of Toxicology · doi:10.1007/s00204-011-0693-2 · Cited by 584
A microfluidic device for a pharmacokinetic–pharmacodynamic (PK–PD) model on a chip
Sung, J. H., Kam, C., & Shuler, M. L. (2010) · Lab on a Chip · doi:10.1039/b917763a · Cited by 484
Self-citationA Review of Three-Dimensional In Vitro Tissue Models for Drug Discovery and Transport Studies
Elliott, N. T., & Yuan, F. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22257 · Cited by 449
Organ-on-a-chip devices advance to market
Zhang, B., & Radisic, M. (2017) · Lab on a Chip · doi:10.1039/c6lc01554a · Cited by 437
Organ-on-a chip systems: microengineering to biomimic living systems
Zheng, F., Fu, F., Cheng, Y., Wang, C., Zhao, Y., & Gu, Z. (2016) · Small · doi:10.1002/smll.201503208 · Cited by 338
The Role of Body-on-a-Chip Devices in Drug and Toxicity Studies
Esch, M. B., King, T. L., & Shuler, M. L. (2011) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-071910-124629 · Cited by 328
Self-citationOrgan-on-a-chip platforms: a convergence of advanced materials, cells, and microscale technologies
Ahadian, S., Civitarese, R., Bannerman, D., Mohammadi, M. H., Lu, R., Wang, E., Davenport‐Huyer, L., Lai, B., Zhang, B., Zhao, Y., et al. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201700506 · Cited by 315
Marx, U. (2016) · ALTEX · doi:10.14573/altex.1603161 · Cited by 295
“Furthermore, two combination therapies using doxorubicin (Tatosian and Shuler, 2009) and tegafur (Sung and Shuler, 2009) have been tested on human cancer cell lines in µCCA layouts specifically developed for substance testing applications.”
Selective isolation of live/dead cells using contactless dielectrophoresis (cDEP)
Shafiee, H., Sano, M. B., Henslee, E. A., Caldwell, J. L., & Davalos, R. V. (2010) · Lab on a Chip · doi:10.1039/b920590j · Cited by 288
Tumor-on-a-chip: from bioinspired design to biomedical application
Liu, X., Fang, J., Huang, S., Wu, X., Xie, X., Wang, J., Liu, F., Zhang, M., Peng, Z., & Hu, N. (2021) · Microsystems & Nanoengineering · doi:10.1038/s41378-021-00277-8 · Cited by 246
Prantil-Baun, R., Novak, R., Das, D., Somayaji, M. R., Przekwas, A., & Ingber, D. E. (2018) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010716-104748 · Cited by 176
Multi-cellular 3D human primary liver cell culture elevates metabolic activity under fluidic flow
Esch, M. B., Prot, J.-M., Wang, Y. I., Miller, P., Llamas-Vidales, J. R., Naughton, B. A., Applegate, D. R., & Shuler, M. L. (2015) · Lab on a Chip · doi:10.1039/c5lc00237k · Cited by 173
Self-citationAnimal tissue culture principles and applications
Verma, A., Verma, M., & Singh, A. (2020) · Animal Biotechnology · doi:10.1016/b978-0-12-811710-1.00012-4 · Cited by 161
Organ-Tumor-on-a-Chip for Chemosensitivity Assay: A Critical Review
Kashaninejad, N., Nikmaneshi, M., Moghadas, H., Kiyoumarsi Oskouei, A., Rismanian, M., Barisam, M., Saidi, M., & Firoozabadi, B. (2016) · Micromachines · doi:10.3390/mi7080130 · Cited by 79
“[41] Silicon (PDMS) 2D tumor/homotypic 2D cell culture Injection of cell suspension) Steady drug compotation MTS DNA [110] PDMS Tumor Invasion and Metastasis 2D 6-well plate Gravitational flow TBE and CMI [117] PDMS 3D tumor spheroids/homotypic HDT for 16-well plate Single pipetting Tree-like steady state ATP [133] PD…”
BackgroundMethodInfluentialImmune Organs and Immune Cells on a Chip: An Overview of Biomedical Applications
Morsink, M., Willemen, N., Leijten, J., Bansal, R., & Shin, S. (2020) · Micromachines · doi:10.3390/mi11090849 · Cited by 73
Sung, J. H., Wang, Y., & Shuler, M. L. (2019) · APL Bioengineering · doi:10.1063/1.5097675 · Cited by 66
Self-citationCritical Considerations for the Design of Multi-Organ Microphysiological Systems (MPS)
Malik, M., Yang, Y., Fathi, P., Mahler, G. J., & Esch, M. B. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.721338 · Cited by 43
In vitro functional models for human liver diseases and drug screening: beyond animal testing
Paradiso, A., Volpi, M., Rinoldi, C., Celikkin, N., Contessi Negrini, N., Bilgen, M., Dallera, G., Pierini, F., Costantini, M., Święszkowski, W., et al. (2023) · Biomaterials Science · doi:10.1039/d1bm01872h · Cited by 40
Metadata
- Authors
- Tatosian, D. A., & Shuler, M. L.
- Venue
- Biotechnology and Bioengineering
- Publisher
- Wiley
- Published
- 2009-01-09
- Volume
- 103
- Issue
- 1
- Pages
- 187-198
- ISSN
- 0006-3592 (ISSN-L)
- 1097-0290
- OpenAlex
- W2022941161
- Cited by
- 149
- References
- 0
- FWCI
- 3.85
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.